Korean cosmetics ODM/OEM manufacturer, one of the world's largest contract makers of skincare and makeup products.
Korean cosmetics ODM/OEM manufacturer, one of the world's largest contract makers of skincare and makeup products.
Works as an original design manufacturer: it develops the formula itself, makes it and sells it to beauty brands that handle marketing and shelf space, so it earns a production margin and its sales follow the brands' demand. Its customer base is spread across many brands.
Moat: narrow (scale, process know-how). Large-scale formulation and manufacturing expertise trusted by many global beauty brands.
Headquarters: Seoul, South Korea · Founded: 1990 · Employees: 1,542
Size Kolmar Korea (161890.KS) is a South Korea Consumer Staples company (Household/Personal Care) with a market value of $2.05B, the 139th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩114,700 on 18 Nov 2026.
Performance Over six months the shares gained 13.8%, against -4.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 15.6% over the last twelve months (peer median +4.3%); the operating margin is 10.4% (peer median 10.6%).
Valuation It trades at 14.3× forward earnings against a peer median of 20.7× (5th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.2 points above its cost of capital (5.5% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩3.07T | ₩2.72T | ₩2.45T | ₩2.16T | ₩1.87T |
| Revenue growth | — | +11% | +14% | +16% | — |
| Gross profit | ₩822B | ₩745B | ₩659B | ₩538B | ₩440B |
| EBITDA | ₩429B | ₩344B | ₩286B | ₩230B | ₩149B |
| Net income | ₩194B | ₩125B | ₩90.1B | ₩5.19B | -₩22.0B |
| Free cash flow | ₩134B | ₩127B | -₩31.8B | ₩5.95B | ₩52.1B |
| Capital expenditure | ₩192B | ₩242B | ₩261B | ₩125B | ₩57.5B |
| Total debt | ₩1.23T | ₩1.23T | ₩1.15T | ₩1.10T | ₩1.07T |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Kolmar Korea 161890.KS | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% |
| Cosmax 192820.KS | $2.51B | +53% | +25% | 8% | 18.8× | n/a |
| Cosmecca Korea 241710.KS | $847M | +23% | +42% | 12% | 16.3× | n/a |
| Intercos ICOS.MI | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 161890.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.8% | +2.2% | 6th lowest of 21 |
| 6-month return | +13.8% | -4.7% | 6th highest of 21 |
| Distance from 52-week high | -30.9% | -24.8% | 8th lowest of 21 |
| Revenue growth (TTM) | +15.6% | +4.3% | 4th highest of 21 |
| Operating margin | 10.4% | 10.6% | 10th lowest of 21 |
| Forward P/E | 14.3× | 20.7× | 5th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -1.6% | 0.3% | 9th least demanding of 17 |
| Growth delivered (Del g) | +15.5% | +4.6% | 4th highest of 17 |
| Hurdle (Req g minus delivered) | -17.2 pp | -3.4 pp | 3rd least demanding of 17 |
| ROIC minus cost of capital | +2.2 pp | +5.4 pp | 7th lowest of 20 |
| EV / EBITDA | 10.3× | 10.3× | 7th most expensive of 14 |
| Net debt / EBITDA | 2.1× | -1.8× | 3rd most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| Intercos ICOS.MI | Italy | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% | +11.5% |